This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
A study that aimed to look at the association between physician burnout and electronic health record message characteristics did not find a strong link, but did reveal opportunities to improve negativity and hostility toward physicians in some messages.
Japanese pharmaceutical company Eisai has denied that two deaths that have sparked concerns about a new Alzheimer's disease drug treatment are attributed to its trials.
VillageMD, a value-based care primary services provider, is expanding access to care through a partnership with Point32Health to offer services in Massachusetts.
Hospitals are still facing tough financial conditions heading into the end of 2022, with the latest National Hospital Flash Report revealing negative margins in October.
This year’s flu season is underway in the United States, and the number of cases is rising, according to the latest flu data from the Centers for Disease Control and Prevention (CDC).
Forbes has announced its annual 30 Under 30 list, highlighting leaders across industries. Within the healthcare space, the list features leaders working to expand access to care and to treat and cure disease.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
